The study concluded that L-FABP, along with three other biomarkers (NGAL/Neutrophil gelatinase-associated lipocalin, IL-18/Interleukin-18, and albumin), has a good and efficient ability to differentiate patients with progressive AKI and cirrhosis. This evidence concerns the gene ALB and acute kidney injury.